ReviewOncology reports2025
Role of miRNA‑214‑3p in cancer (Review).
Review in Oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
microRNA‑214‑3p (miRNA‑214‑3p) can be mapped to the human chromosome 1q24.3 and is ~22 nucleotides in length. It has been garnering considerable attention due to its aberrant expression profile in various different types of cancer and its apparent role in regulating tumor progression. In malignant tumors, miRNA‑214‑3p can serve as a tumor suppressor or oncogene. This can be mediated by mainly inhibiting the expression of target genes by binding to the 3'‑untranslated region of target mRNAs, thereby regulating multiple downstream cellular processes, such as cell proliferation, metastasis, invasion and apoptosis. However, the role of miRNA‑214‑3p in cancer remains unclear. Therefore, in the present review, the role of miRNA‑214‑3p in cancer was summarized, whilst analyzing its potential as a biomarker for cancer diagnosis, prognosis and response to treatment. In addition, the present review evaluates its effects on sensitivity to chemotherapy, targeted therapy and radiotherapy. The current proposed strategies for the systemic delivery of miRNA‑214‑3p in cancer were also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.